Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
Clinical and Molecular Hepatology · 2023
DOI: 10.3350/cmh.2023.0194 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Molecular Hepatology, 2023. Verfasst von Ying-Nan Tsai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B Core Antigens, Hepatitis B, Chronic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: E-Da Hospital, National Science and Technology Council in Taiwan, Tomorrow Medical Foundation.
Abstract (Originalsprache)
Background/Aims: Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring hepatitis B core-related antigen (HBcrAg) after NA cessation may stratify the risk of subsequent clinical relapse (CR).
Methods
This retrospective multicenter analysis enrolled adults with CHB who were prospectively monitored after discontinuing entecavir or tenofovir with negative HBeAg and undetectable HBV DNA at the end of treatment (EOT). Patients with cirrhosis or malignancy were excluded. CR was defined as serum alanine aminotransferase > two times the upper limit of normal with recurrent viremia. We applied time-dependent Cox proportional hazard models to clarify the association between HBcrAg levels and subsequent CR.
Results
The cohort included 203 patients (median age, 49.8 years; 76.8% male; 60.6% entecavir) who had been treated for a median of 36.9 months (interquartile range [IQR], 36.5–40.1). During a median post-treatment follow-up of 31.7 months (IQR, 16.7–67.1), CR occurred in 104 patients with a 5-year cumulative incidence of 54.8% (95% confidence interval [CI], 47.1–62.4%). Time-varying HBcrAg level was a significant risk factor for subsequent CR (adjusted hazard ratio [aHR], 1.53 per log U/mL; 95% CI, 1.12–2.08) with adjustment for EOT HBsAg, EOT anti-HBe, EOT HBcrAg and time-varying HBsAg. During follow-up, HBcrAg
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Department of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan.
- Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Förderung
- E-Da Hospital
- National Science and Technology Council in Taiwan
- Tomorrow Medical Foundation
Zitieren
APA
Tsai, Y. N., Wu, J. L., Tseng, C. H., Chen, T. H., Wu, Y. L., Chen, C. C., Fang, Y. J., Yang, T. H., Nguyen, M. H., Lin, J. T., & Hsu, Y. C. (2023). Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2023.0194
Vancouver
Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, et al. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation. Clinical and Molecular Hepatology. 2023. doi:10.3350/cmh.2023.0194
BibTeX
@article{Tsai2023,
author = {Tsai, Ying-Nan and Wu, Jia-Ling and Tseng, Cheng-Hao and Chen, Tzu-Haw and Wu, Yi-Ling and Chen, Chieh-Chang and Fang, Yu-Jen and Yang, Tzeng-Huey and Nguyen, Mindie H and Lin, Jaw-Town and Hsu, Yao-Chun},
title = {Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation},
journal = {Clinical and Molecular Hepatology},
year = {2023},
doi = {10.3350/cmh.2023.0194}
}
EUVIMED